Article Text

Download PDFPDF
Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with radiotherapy alone
  1. P. PAUTIER*,
  2. A. REY,
  4. P. KERBRAT§,
  5. J. L. DUTEL,
  6. P. GESTA**,
  7. F. BRYARD††,
  8. P. MORICE‡‡,
  9. P. DUVILLARD§§ and
  10. C. LHOMMÉ*
  1. *Department of Medical Oncology, Institut Gustave-Roussy, Villejuif, France
  2. Department of Biostatistics, Institut Gustave-Roussy, Villejuif, France
  3. Department of Radiotherapy, Institut Gustave-Roussy, Villejuif, France
  4. §Department of Medical Oncology, Centre Eugène-Marquis, Rennes, France
  5. Hôpital de Beauvais, Beauvais, France
  6. **Centre hospitalier de Niort, Niort, France
  7. ††Centre hospitalier de Sens, Institut Gustave-Roussy, Villejuif, France
  8. ‡‡Department of Surgery, Institut Gustave-Roussy, Villejuif, France
  9. §§Department of Pathology, Institut Gustave-Roussy, Villejuif, France
  1. Address correspondence and reprint requests to: Dr Patricia Pautier, Service de Gynécologie Médicale, Institut Gustave-Roussy, 39 rue Camille-Desmoulins, 94805 Villejuif Cedex, France. Email: pautier{at}


Uterine sarcoma is a poor prognosis disease, with a high risk of metastatic relapse. We conducted a study of adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy (n = 18). The results were then compared in a matched case-controlled study to radiotherapy alone (n = 16) or no therapy at all (n = 2). Chemotherapy consisted in three cycles of adriamyein-platinum-ifosfamide (API) (doxorubicin 60 mg /m2 on day 1; cisplatin 100 mg /m2 on day 2; ifosfamide 5 g /m2 on day 1 + mesna 5 g /m2 on day 1 + granulocyte colony-stimulating factor; q 3 weeks). Drug doses were reduced (20% for ifosfamide and cisplatin) four times (four patients) due to hematologic toxicity. Compared to a case-control study of adjuvant radiotherapy alone, results were not decreased by the addition of a toxic chemotherapy.

Conclusion Adjuvant API chemotherapy followed by radiotherapy is a feasible protocol; a multicenter phase III study comparing radiotherapy alone versus API chemotherapy followed by radiotherapy just began in France.

  • adjuvant
  • chemotherapy
  • sarcoma
  • treatment
  • uterine

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.